Literature DB >> 24027430

Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.

Aishwarya G Jacob1, Dennis O'Brien, Ravi K Singh, Daniel F Comiskey, Robert M Littleton, Fuad Mohammad, Jordan T Gladman, Maria C Widmann, Selvi C Jeyaraj, Cheryl Bolinger, James R Anderson, Donald A Barkauskas, Kathleen Boris-Lawrie, Dawn S Chandler.   

Abstract

Pediatric rhabdomyosarcoma (RMS) is a morphologically and genetically heterogeneous malignancy commonly classified into three histologic subtypes, namely, alveolar, embryonal, and anaplastic. An issue that continues to challenge effective RMS patient prognosis is the dearth of molecular markers predictive of disease stage irrespective of tumor subtype. Our study involving a panel of 70 RMS tumors has identified specific alternative splice variants of the oncogenes Murine Double Minute 2 (MDM2) and MDM4 as potential biomarkers for RMS. Our results have demonstrated the strong association of genotoxic-stress inducible splice forms MDM2-ALT1 (91.6% Intergroup Rhabdomyosarcoma Study Group stage 4 tumors) and MDM4-ALT2 (90.9% MDM4-ALT2-positive T2 stage tumors) with high-risk metastatic RMS. Moreover, MDM2-ALT1-positive metastatic tumors belonged to both the alveolar (50%) and embryonal (41.6%) subtypes, making this the first known molecular marker for high-grade metastatic disease across the most common RMS subtypes. Furthermore, our results show that MDM2-ALT1 expression can function by directly contribute to metastatic behavior and promote the invasion of RMS cells through a matrigel-coated membrane. Additionally, expression of both MDM2-ALT1 and MDM4-ALT2 increased anchorage-independent cell-growth in soft agar assays. Intriguingly, we observed a unique coordination in the splicing of MDM2-ALT1 and MDM4-ALT2 in approximately 24% of tumor samples in a manner similar to genotoxic stress response in cell lines. To further explore splicing network alterations with possible relevance to RMS disease, we used an exon microarray approach to examine stress-inducible splicing in an RMS cell line (Rh30) and observed striking parallels between stress-responsive alternative splicing and constitutive splicing in RMS tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24027430      PMCID: PMC3769884          DOI: 10.1593/neo.13286

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  66 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.

Authors:  R J Davis; F G Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  The 5' RNA terminus of spleen necrosis virus stimulates translation of nonviral mRNA.

Authors:  T M Roberts; K Boris-Lawrie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation.

Authors:  Manuel J Muñoz; M Soledad Pérez Santangelo; Maria P Paronetto; Manuel de la Mata; Federico Pelisch; Stéphanie Boireau; Kira Glover-Cutter; Claudia Ben-Dov; Matías Blaustein; Juan J Lozano; Gregory Bird; David Bentley; Edouard Bertrand; Alberto R Kornblihtt
Journal:  Cell       Date:  2009-05-15       Impact factor: 41.582

5.  Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.

Authors:  J Lukas; D Q Gao; M Keshmeshian; W H Wen; D Tsao-Wei; S Rosenberg; M F Press
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

6.  P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.

Authors:  A C Taylor; L Shu; M K Danks; C A Poquette; S Shetty; M J Thayer; P J Houghton; L C Harris
Journal:  Med Pediatr Oncol       Date:  2000-08

7.  The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth.

Authors:  Patima Sdek; Haoqiang Ying; Hongwu Zheng; Alexander Margulis; Xiaoren Tang; Kui Tian; Zhi-Xiong Jim Xiao
Journal:  J Biol Chem       Date:  2004-10-13       Impact factor: 5.157

Review 8.  Hallmarks of senescence in carcinogenesis and cancer therapy.

Authors:  Jerry W Shay; Igor B Roninson
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

9.  MDM2-A, a common Mdm2 splice variant, causes perinatal lethality, reduced longevity and enhanced senescence.

Authors:  Erin L Volk; Katja Schuster; Katie M Nemeth; Liying Fan; Linda C Harris
Journal:  Dis Model Mech       Date:  2008-12-22       Impact factor: 5.758

10.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.

Authors:  Andrea Prodosmo; Simona Giglio; Sonia Moretti; Francesca Mancini; Flavia Barbi; Nicola Avenia; Giusy Di Conza; Holger J Schünemann; Lorenza Pistola; Vienna Ludovini; Ada Sacchi; Alfredo Pontecorvi; Efisio Puxeddu; Fabiola Moretti
Journal:  J Mol Med (Berl)       Date:  2008-03-12       Impact factor: 4.599

View more
  15 in total

1.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  Alternative splicing of MEF2C pre-mRNA controls its activity in normal myogenesis and promotes tumorigenicity in rhabdomyosarcoma cells.

Authors:  Meiling Zhang; Bo Zhu; Judith Davie
Journal:  J Biol Chem       Date:  2014-11-17       Impact factor: 5.157

3.  The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA.

Authors:  Aishwarya G Jacob; Ravi K Singh; Fuad Mohammad; Thomas W Bebee; Dawn S Chandler
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

Review 4.  Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Authors:  Xuetian Yue; Yuhan Zhao; Yang Xu; Min Zheng; Zhaohui Feng; Wenwei Hu
Journal:  J Mol Biol       Date:  2017-04-06       Impact factor: 5.469

Review 5.  The Roles of MDM2 and MDMX in Cancer.

Authors:  Orit Karni-Schmidt; Maria Lokshin; Carol Prives
Journal:  Annu Rev Pathol       Date:  2016-03-17       Impact factor: 23.472

Review 6.  Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Int J Cancer       Date:  2016-02-08       Impact factor: 7.396

7.  Genome-wide profiling of prognosis-related alternative splicing signatures in sarcoma.

Authors:  Weifeng Hong; Weicong Zhang; Renguo Guan; Yuying Liang; Shixiong Hu; Yayun Ji; Mouyuan Liu; Hai Lu; Min Yu; Liheng Ma
Journal:  Ann Transl Med       Date:  2019-10

8.  Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage.

Authors:  Daniel F Comiskey; Aishwarya G Jacob; Ravi K Singh; Aixa S Tapia-Santos; Dawn S Chandler
Journal:  Nucleic Acids Res       Date:  2015-04-06       Impact factor: 16.971

9.  Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.

Authors:  Aishwarya G Jacob; Ravi K Singh; Daniel F Comiskey; Matthew F Rouhier; Fuad Mohammad; Thomas W Bebee; Dawn S Chandler
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

10.  Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.

Authors:  Beibei Ni; Jun Hu; Dianke Chen; Li Li; Daici Chen; Jianping Wang; Lei Wang
Journal:  Oncol Lett       Date:  2016-07-13       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.